Shang­hai-based can­cer drug­mak­er Ab­bisko lines up $42M B round as it makes a leap for the clin­ic

Qim­ing Ven­tures is lead­ing a B round for Ab­bisko Ther­a­peu­tics, more than dou­bling the Shang­hai-based biotech’s pre­vi­ous haul as it hus­tles a pair of home­grown …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.